Drug intelligence / Profile preview

[18F]FEMPA

Development stage: Phase 1
Lead developer: Bayer
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration: Intravenous

Overview

[18F]FEMPA (BAY1006578) is a radiolabeled small molecule developed as a positron emission tomography (PET) imaging agent. It was investigated for its diagnostic potential in distinguishing probable Alzheimer's disease patients from healthy volunteers by visualizing specific brain targets using PET imaging. The compound is used as a tracer to assess pathological changes associated with Alzheimer's disease, aiding in the evaluation of neurodegenerative processes. The developer of this agent is Bayer. Its primary indication has been for diagnostic imaging in Alzheimer’s disease research, and it has undergone phase 1 clinical trials for this purpose.

Targets

TSPO (Translocator Protein (18 kDa))

Beyond the preview

Go deeper on [18F]FEMPA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]FEMPA.